Ildong to continue oral 'GLP-1 receptor agonist' trial

in Kor

Ildong aims to potentially develop new drug targeting type 2 diabetes and obesity

Ildong Pharmaceutical will conduct an additional round of Phase 1 clinical trial for its proprietary new drug candidate, 'ID110521156,' for the treatment of type 2 diabetes.

 

The drug, by the development code ID110521156, is an oral new drug targeting type 2 diabetes and obesity.

 

On August 20th, the Ministry of Food and Drug Safety (MFDS) approved a 'Randomized, double-blind, placebo-controlled, multiple-ascending oral dose Phase 1 study of ID110521156 in healthy adults to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of the drug,' which has been submitted by Unovia.

 

Unovia is an independent company established through a simple asset split by Ildong Pharmaceutical to spin off its R&D division.

 

Ildong Pharmaceutical holds 100% of Unovia's shares as the parent company.

 

The Phase 1 trial for ID11052115 was conducted from September 2023 to February 2024 in South Korea.

 

The previous goal was to study 'single oral administration,' but this time, the study will evaluate the drug's safety by multiple-dose administration of ID110521156.

 

When the clinical trial is completed successfully, Ildong Pharmaceutical plans to develop the new drug candidate as an oral new drug targeting type 2 diabetes and obesity.

 

ID110521156 is a type of glucagon-like peptide-1 receptor agonist, and it works as an analog of GLP-1 hormone that induces insulin secretion in the body and regulates blood sugar levels.

 

GLP-1 hormone is synthesized in the beta cells of the pancreas.

 

It is known to be involved in insulin synthesis and secretion in the body, reducing blood sugar levels, regulating gastrointestinal movement, and suppressing appetite.

 

ID110521156 is a small-molecule compound with the same function as GLP-1 hormones.

 

It is structurally more stable and has a longer plasma half-life than peptide-based biological agents.

 

The company explained that ID110521156's efficacy and toxicity evaluations using disease animal models have demonstrated significant effectiveness in insulin secretion and blood glucose control and superior safety compared to competing drugs in the same class.

 

The company has already registered the candidate's substance patent in countries including South Korea, the United States, China, Japan, India, and Australia.

 

Ildong Pharmaceutical's official stated, "We have evaluated the efficacy and toxicity profile of ID110521156 using disease animal models and have confirmed its effectiveness in insulin secretion, blood glucose control, and safety," and added, "We are currently in discussions with several global pharmaceutical companies regarding licensing and partnerships."